Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board for hybrid drug endeavor
Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board for hybrid drug endeavor
This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source. Tsur and Bennett founded Cyota in 1999 together with Ben Enosh and Lior Golan and sold it to RSA Security in 2005 for $145 million
Former Prime Minister of Israel, Naftali Bennett, is joining the board of Remepy, co-founded by Dr. Michal Tsur, his former co-founder from Cyota and co-founder of Kaltura. “I am proud to join Remepy’s journey to develop a new category of hybrid medications, and happy to collaborate again with Michal,” said Bennett.
This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source.
"The products that Naftali and I developed together at Cyota still serve bank customers around the world to this day, and I am proud of that,” said Tsur. “Remepy is pioneering hybrid drugs, and leading the way in designing and measuring the mechanisms of influence of digital interactions on patients and in harnessing the digital world to improve the effectiveness of medications.”
Tsur and Bennett founded Cyota in 1999 together with Ben Enosh and Lior Golan and sold it to RSA Security in 2005 for $145 million. Cyota was an Israeli information security company that specialized in software and services for securing online banking, as well as securing online credit card transactions.
Related articles:
- Former Israeli Prime Minister Naftali Bennett joins Quantum Source Board of Directors
- “Israel must position itself as one of the three leading AI powers in the world,” says former Prime Minister Bennett
- Gigi Levy-Weiss: “I have no doubt the Israeli ‘Startup Nation’ brand will thrive for years to come”
Remepy is developing Hybrid Drugs: Drugs that include therapeutic applications that enhance the drug effect. The company has demonstrated in early clinical studies the physiological effect of its digital interventions using fMRI scans, and blood samples. The effects demonstrated in its recent studies have the potential to improve drugs and impact medical outcomes in neurological diseases, cancer, autoimmune diseases, and degenerative eye diseases.
Remepy was founded about a year ago by Tsur, Or Shoval, and Prof. Amir Amedi, who heads the Brain and Imaging Research Institute at Reichman University.
“Israeli technology plays a critical role both in the fight against Terror and in the economic recovery of Israel post-conflict. I am especially proud of all the entrepreneurs who continue to build and grow companies even in times of war, and am glad to contribute my part,” said Bennett.
